DexCom (DXCM) Competitors $68.20 -1.31 (-1.88%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$68.24 +0.04 (+0.06%) As of 09/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DXCM vs. HQY, PODD, ABT, AMN, ITGR, BDX, IDXX, EW, RMD, and STEShould you be buying DexCom stock or one of its competitors? The main competitors of DexCom include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), Integer (ITGR), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), and STERIS (STE). These companies are all part of the "medical" sector. DexCom vs. Its Competitors HealthEquity Insulet Abbott Laboratories AMN Healthcare Services Integer Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences ResMed STERIS DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Do insiders and institutionals hold more shares of DXCM or HQY? 97.8% of DexCom shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 1.5% of HealthEquity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, DXCM or HQY? DexCom has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Do analysts recommend DXCM or HQY? DexCom currently has a consensus target price of $99.89, indicating a potential upside of 46.47%. HealthEquity has a consensus target price of $119.77, indicating a potential upside of 27.62%. Given DexCom's higher probable upside, analysts plainly believe DexCom is more favorable than HealthEquity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 5 Hold rating(s) 14 Buy rating(s) 3 Strong Buy rating(s) 2.91HealthEquity 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer DXCM or HQY? In the previous week, DexCom had 21 more articles in the media than HealthEquity. MarketBeat recorded 30 mentions for DexCom and 9 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.30 beat DexCom's score of 0.90 indicating that HealthEquity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 16 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DXCM or HQY more profitable? DexCom has a net margin of 13.29% compared to HealthEquity's net margin of 11.49%. DexCom's return on equity of 30.41% beat HealthEquity's return on equity.Company Net Margins Return on Equity Return on Assets DexCom13.29% 30.41% 10.08% HealthEquity 11.49%12.04%7.44% Which has higher valuation and earnings, DXCM or HQY? DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.30B6.22$576.20M$1.4447.36HealthEquity$1.20B6.74$96.70M$1.6556.88 SummaryDexCom beats HealthEquity on 10 of the 17 factors compared between the two stocks. Get DexCom News Delivered to You Automatically Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXCM vs. The Competition Export to ExcelMetricDexComMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.26B$6.83B$5.76B$10.51BDividend YieldN/A1.20%5.53%4.57%P/E Ratio47.3625.7676.4326.62Price / Sales6.22194.61473.6992.75Price / Cash30.9321.9037.4661.85Price / Book12.685.0513.616.45Net Income$576.20M$178.07M$3.29B$271.57M7 Day Performance-10.78%2.19%1.87%2.61%1 Month Performance-17.09%6.81%4.03%7.28%1 Year Performance-0.67%23.10%77.41%29.60% DexCom Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXCMDexCom4.9748 of 5 stars$68.20-1.9%$99.89+46.5%-2.2%$27.26B$4.30B47.3610,300HQYHealthEquity4.3698 of 5 stars$93.02+0.6%$119.77+28.8%+18.5%$8.01B$1.20B56.383,120Positive NewsInsider TradePODDInsulet4.6049 of 5 stars$340.29-0.4%$335.12-1.5%+37.2%$23.95B$2.07B103.433,900ABTAbbott Laboratories4.94 of 5 stars$131.40-1.7%$144.47+9.9%+18.3%$228.70B$41.95B16.47114,000Positive NewsDividend AnnouncementAMNAMN Healthcare Services4.7449 of 5 stars$18.21-0.2%$23.25+27.7%-58.5%$697.62M$2.98B-2.342,968ITGRInteger3.9355 of 5 stars$100.11-1.2%$140.25+40.1%-19.6%$3.51B$1.79B44.1011,000Positive NewsBDXBecton, Dickinson and Company4.9608 of 5 stars$185.90-0.5%$211.44+13.7%-20.6%$53.29B$21.39B33.4474,000Positive NewsIDXXIDEXX Laboratories4.1402 of 5 stars$643.99+0.4%$649.44+0.8%+27.7%$51.52B$4.04B53.6211,000Positive NewsEWEdwards Lifesciences4.7356 of 5 stars$76.10-1.9%$86.26+13.4%+10.8%$44.68B$5.44B10.9515,800Positive NewsAnalyst UpgradeRMDResMed4.6726 of 5 stars$271.39+0.5%$278.36+2.6%+12.0%$39.74B$5.15B28.5410,600Positive NewsSTESTERIS4.8865 of 5 stars$247.71-0.9%$273.50+10.4%+4.1%$24.40B$5.46B37.9317,787 Related Companies and Tools Related Companies HealthEquity Competitors Insulet Competitors Abbott Laboratories Competitors AMN Healthcare Services Competitors Integer Competitors Becton, Dickinson and Company Competitors IDEXX Laboratories Competitors Edwards Lifesciences Competitors ResMed Competitors STERIS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXCM) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
